evaluations+economics

Hospital-based psychologists are sorely undervalued.

Dr. Jen Ashton has the latest theories on the origins of SARS-CoV-2.

Market review and policy overview.

Fiscal Year 2019/20 Snapshot Report

About 1 in 5 U.S. adults have skipped healthcare over the past year because they couldn't afford it.

A long-awaited report from the World Health Organisation into the origin of COVID-19 virus favour transmission from animals, instead of a leak from a laboratory.

WHO-convened Global Study of the Origins of SARS-CoV-2

The 10 most expensive drugs in the United States.

The troubling signs come despite more than one-third of American adults now having received at least one Covid-19 shot.

A 2019 review of major recent U.S. federal proposals that affect drug pricing in oncology for both drugs administered under Medicare Part B and Part D.

Every year, significant amounts of expensive drugs are discarded.

A growing number of increasingly expensive, specialized treatments are driving overall costs higher.

Annual Report 2019

An Examination of Patents and Orphan Drug Exclusivity

This 2021 paper analyzes the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) across three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States.